Floatz logo

Romidepsin

Leukemia, Lymphocytic

Dartmouth-Hitchcock Medical CenterSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Leukemia, Lymphocytic cohort.

Asset / SponsorPhaseRating
Fludarabine
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Busulphan
Dartmouth-Hitchcock Medical Center
Phase 4BB
Pirtobrutinib
Loxo Oncology, Inc.
Phase 3BB
(+)-VINCRISTINE
Children's Oncology Group
Phase 2B
Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B

View all 15 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →